1. World Health Organization WHO factsheet 211: influenza; 2003.
2. Arnold S. Monto, MD. Am J Manag Care 6 (2000) Epidemiology and virology of influenza illness. S255-264.
3. Treanor J (2004) Influenza vaccine--outmaneuvering antigenic shift and drift. N Engl J Med 350: 218-220.
4. Medina, R. A. and Garcia-Sastre, A. (2011) Influenza A viruses: new research developments. Nat Rev Microbiol 9: 590-603.
5. Webstar, R.G, et al. (1992) Evolution and ecology of influenza A viruses. Microbiolo Rev 56: 152-179.
6. Smith, W., C.H, Andrewes, and P.P. Laidlaw (1933) A virus obtained form influenza patients. Lancet 2: 66-68.
7. Taubenberger JK, Morens DM (2006) 1918 Influenza: the mother of all pandemics. Emerg Infect Dis 12: 15-22.
8. Fouchier RA, Munster V, Wallensten A, Bestebroer TM, Herfst S, et al. (2005) Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol 79: 2814-2822.
9. Soema PC, Kompier R, Amorij JP, Kersten GF (2015) Current and next generation influenza vaccines: Formulation and production strategies. Eur J Pharm Biopharm 94: 251-263.
10. Both GW, Sleigh MJ, Cox NJ, Kendal AP (1983) Antigenic drift in influenza virus H3 hemagglutinin from 1968 to 1980: multiple evolutionary pathways and sequential amino acid changes at key antigenic sites. J Virol 48: 52-60.
11. Cox NJ, Subbarao K (2000) Global epidemiology of influenza: past and present. Annu Rev Med 51: 407-421.
12. Neumann G, Noda T, Kawaoka Y (2009) Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459: 931-939.
13. World Health Organization: H5N1 avian influenza;http://www.who.int/csr/disease/avian_influenza/ai_time;ine.htm
14. Okazaki K, Takada A, Ito T, Imai M, Takakuwa H, et al. (2000) Precursor genes of future pandemic influenza viruses are perpetuated in ducks nesting in Siberia. Arch Virol. 145:885-893.
15. Imai M, Watanabe T, Hatta M, Das SC, Ozawa M,et al. (2012) Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486:420-428
16. Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, et al. (2005) Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366: 1175-1181.
17. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI (2006) Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295: 891-894.
18. Hui DS, Lee N, Chan PK (2010) Clinical management of pandemic 2009 influenza A(H1N1) infection. Chest 137: 916-925.
19. Hatakeyama S. (2010) Drug-resistant influenza viruses: an overview. Nippon Rinsho 68:1671-1678.
20. Ye Q, Krug RM, Tao YJ (2006) The mechanism by which influenza A virus nucleoprotein forms oligomers and binds RNA. Nature 444: 1078-1082.
21. Arranz R, Coloma R, Chichon FJ, Conesa JJ, Carrascosa JL, et al. (2012) The structure of native influenza virion ribonucleoproteins. Science 338: 1634-1637.
22. Moeller A, Kirchdoerfer RN, Potter CS, Carragher B, Wilson IA (2012) Organization of the influenza virus replication machinery. Science 338: 1631-1634.
23. Ye Q, Guu TS, Mata DA, Kuo RL, Smith B, et al. (2012) Biochemical and structural evidence in support of a coherent model for the formation of the double-helical influenza A virus ribonucleoprotein. MBio 4: e00467-00412.
24. Aida Y, Sasaki Y, Hagiwara K (2012) Discovery of Novel Antiviral Agents Directed Against the Influenza A Virus Nucleoprotein. Antiviral Drugs—Aspects of Clinical Use and Recent Advances; 99–120.
25. Yu M, Liu X, Cao S, Zhao Z, Zhang K, et al. (2012) Identification and characterization of three novel nuclear export signals in the influenza A virus nucleoprotein. J Virol 86: 4970-4980.
26. Li Z, Watanabe T, Hatta M, Watanabe S, Nanbo A, et al. (2009) Mutational analysis of conserved amino acids in the influenza A virus nucleoprotein. J Virol 83: 4153-4162.
27. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y (1992) Evolution and ecology of influenza A viruses. Microbiol Rev 56: 152-179.
28. Cianci C, Gerritz SW, Deminie C, Krystal M (2012) Influenza nucleoprotein: promising target for antiviral chemotherapy. Antivir Chem Chemother 23: 77-91.
29. Hagiwara K, Kondoh Y, Ueda A, Yamada K, Goto H, et al. (2010) Discovery of novel antiviral agents directed against the influenza A virus nucleoprotein using photo-cross-linked chemical arrays. Biochem Biophys Res Commun 394: 721-727.
30. Shen YF, Chen YH, Chu SY, Lin MI, Hsu HT, et al. (2011) E339...R416 salt bridge of nucleoprotein as a feasible target for influenza virus inhibitors. Proc Natl Acad Sci U S A 108: 16515-16520.
31. Kao RY, Yang D, Lau LS, Tsui WH, Hu L, et al. (2010) Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol 28: 600-605.
32. Gerritz SW, Cianci C, Kim S, Pearce BC, Deminie C, et al. (2011) Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers. Proc Natl Acad Sci U S A 108: 15366-15371.
33. Chou YY, Heaton NS, Gao Q, Palese P, Singer RH, et al. (2013) Colocalization of different influenza viral RNA segments in the cytoplasm before viral budding as shown by single-molecule sensitivity FISH analysis. PLoS Pathog 9: e1003358.
34. ChemSpider database, http://www.simbiosys.ca/ehits_lasso/LASSO_on_ ChemSpider.pdf.
35. M.I. Davis, J.P. Hunt, S. Herrgard, P. Ciceri, L.M. Wodicka, G. Pallares, M. Hocker, D.K. Treiber, P.P. Zarrinkar. (2011) Comprehensive analysis of kinase inhibitor selectivity, Nat. Biotechnol. 29: 1046–1051.
36. Jacoby E, Tresadern G, Bembenek S, Wroblowski B, Buyck C, Neefs JM, Rassokhin D, Poncelet A, Hunt J, van Vlijmen H. (2015) Extending kinome coverage by analysis of kinase inhibitor broad profiling data. Drug Discov Today. 20:652-658.
37. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, et al. (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 30: 2785-2791.
38. Molecular Operating Environment (MOE), 2013.08; Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2014.
39. Ito J, Tabei Y, Shimizu K, Tsuda K, Tomii K (2012) PoSSuM: a database of similar protein-ligand binding and putative pockets. Nucleic Acids Res 40: D541-548.
40. Konc J, Janezic D (2012) ProBiS-2012: web server and web services for detection of structurally similar binding sites in proteins. Nucleic Acids Res 40: W214-221.
41. Chase GP, Rameix-Welti MA, Zvirbliene A, Zvirblis G, Gotz V, et al. (2011) Influenza virus ribonucleoprotein complexes gain preferential access to cellular export machinery through chromatin targeting. PLoS Pathog 7: e1002187.
42. Okomo-Adhiambo M, Demmler-Harrison GJ, Deyde VM, Sheu TG, Xu X, et al. (2010) Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob Agents Chemother 54: 1834–1841.
43. Chutiwitoonchai N, Kakisaka M, Yamada K, Aida Y (2014) Comparative analysis of seven viral nuclear export signals (NESs) reveals the crucial role of nuclear export mediated by the third NES consensus sequence of nucleoprotein (NP) in influenza A virus replication. PLoS One 9: e105081.
44. Elton D, Simpson-Holley M, Archer K, Medcalf L, Hallam R, et al. (2001) Interaction of the influenza virus nucleoprotein with the cellular CRM1-mediated nuclear export pathway. J Virol 75: 408-419.
45. Dias A, Bouvier D, Crepin T, McCarthy AA, Hart DJ, et al. (2009) The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature 458: 914-918.
46. Yuan P, Bartlam M, Lou Z, Chen S, Zhou J, et al. (2009) Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease active site. Nature 458: 909-913.
47. DuBois RM, Slavish PJ, Baughman BM, Yun MK, Bao J, et al. (2012) Structural and biochemical basis for development of influenza virus inhibitors targeting the PA endonuclease. PLoS Pathog 8: e1002830.
48. Sasaki Y, Kakisaka M, Chutiwitoonchai N, Tajima S, Hikono H, et al. (2014) Identification of a novel multiple kinase inhibitor with potent antiviral activity against influenza virus by reducing viral polymerase activity. Biochem Biophys Res Commun 450: 49-54.
49. T. Watanabe, S. Watanabe, Y. Kawaoka.(2010) Cellular networks involved in the influenza virus life cycle, Cell Host Microbe 7:427–439.
50. Karlas, A., Machuy, N., Shin, Y., Pleissner, K.P., Artarini, A., Heuer, D., Becker, D., Khalil, H., Ogilvie, L.A., Hess, S., et al. (2010). Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature 463: 818–822.
51 K.H. Muller, L. Kakkola, A.S. Nagaraj, A.V. Cheltsov, M. Anastasina, D.E. Kainov. (2012) Emerging cellular targets for influenza antiviral agents. Trends Pharmacol. Sci. 33: 89–99.
52. E.C. Hutchinson, E.M. Denham, B. Thomas, D.C. Trudgian, S.S. Hester, G.Ridlova, A. York, L. Turrell, E. Fodor. (2012) Mapping the phosphoproteome of influenza A and B viruses by mass spectrometry. PLoS Pathog. 8: e1002993.
53. Chenavas S, Estrozi LF, Slama-Schwok A, Delmas B, Di Primo C, et al. (2013) Monomeric nucleoprotein of influenza A virus. PLoS Pathog 9: e1003275.
54. Yasuda J, Nakada S, Kato A, Toyoda T, Ishihama A (1993) Molecular assembly of influenza virus: association of the NS2 protein with virion matrix. Virology 196: 249-255.
55. Akarsu H, Burmeister WP, Petosa C, Petit I, Muller CW, et al. (2003) Crystal structure of the M1 protein-binding domain of the influenza A virus nuclear export protein (NEP/NS2). EMBO J 22: 4646-4655.
56. Shimizu T, Takizawa N, Watanabe K, Nagata K, Kobayashi N (2011) Crucial role of the influenza virus NS2 (NEP) C-terminal domain in M1 binding and nuclear export of vRNP. FEBS Lett 585: 41-46.
57. Ye Z, Liu T, Offringa DP, McInnis J, Levandowski RA (1999) Association of influenza virus matrix protein with ribonucleoproteins. J Virol 73: 7467-7473.
58. Noton SL, Medcalf E, Fisher D, Mullin AE, Elton D, et al. (2007) Identification of the domains of the influenza A virus M1 matrix protein required for NP binding, oligomerization and incorporation into virions. J Gen Virol 88: 2280-2290.
59. Ng AK, Zhang H, Tan K, Li Z, Liu JH, et al. (2008) Structure of the influenza virus A H5N1 nucleoprotein: implications for RNA binding, oligomerization, and vaccine design. FASEB J 22: 3638-3647.
60. Sun Q, Carrasco YP, Hu Y, Guo X, Mirzaei H, et al. (2013) Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. Proc Natl Acad Sci U S A 110: 1303-1308.54
61. Su CY, Cheng TJ, Lin MI, Wang SY, Huang WI, et al. (2010) High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity. Proc Natl Acad Sci U S A 107: 19151-19156.
62. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, et al. (2002) In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 46: 977-981.
63. Arnott JA, Planey SL (2012) The influence of lipophilicity in drug discovery and design. Expert Opin Drug Discov 7: 863-875
64. Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10: 1093-1095.
65. Sasaki Y, Hagiwara K, Kakisaka M, Yamada K, Murakami T, et al. (2013) Importin alpha3/Qip1 is involved in multiplication of mutant influenza virus with alanine mutation at amino acid 9 independently of nuclear transport function. PLoS One 8: e55765.
66. Cros JF, Garcia-Sastre A, Palese P (2005) An unconventional NLS is critical forthe nuclear import of the influenza A virus nucleoprotein and ribonucleoprotein.Traffic 6: 205–213.
67. Kakisaka M, Sasaki Y, Yamada K, Kondoh Y, Hikono H, Osada H, Tomii K, Saito T, Aida Y. (2015) A Novel Antiviral Target Structure Involved in the RNA Binding, Dimerization, and Nuclear Export Functions of the Influenza A Virus Nucleoprotein. PLoS Pathog. 11:e1005062. .
68. O’Neill RE, Talon J, Palese P (1998) The influenza virus NEP (NS2 protein) mediates the nuclear export of viral ribonucleoproteins. EMBO J 17: 288–296.
69.Huang S, Chen J, Chen Q, Wang H, Yao Y, et al. (2013) A second CRM1- dependent nuclear export signal in the influenza A virus NS2 protein contributes to the nuclear export of viral ribonucleoproteins. J Virol 87: 767–778.
70.Li Y, Yamakita Y, Krug RM (1998) Regulation of a nuclear export signal by an adjacent inhibitory sequence: the effector domain of the influenza virus NS1 protein. Proc Natl Acad Sci U S A 95: 4864–4869.
71. Cao S, Liu X, Yu M, Li J, Jia X, et al. (2012) A nuclear export signal in the matrix protein of Influenza A virus is required for efficient virus replication. J Virol 86: 4883–4891.
72. Watanabe, K., Noda, S., Kobayashi, N. (2008). Establishment of a new cell line forperforming sensitive screening of nuclear export inhibitors. Drug Discov. Ther. 2: 7–9.
73. la Cour T, Kiemer L, Molgaard A, Gupta R, Skriver K, et al. (2004) Analysis and prediction of leucine-rich nuclear export signals. Protein Eng Des Sel 17: 527–536.
74. Wen, W., Meinkoth, J.L., Tsien, R.Y., Taylor, S.S. (1995) Identification of a signal forrapid export of proteins from the nucleus. Cell 82 :463–473.
75 Zhang, J.H., Chung, T.D., Oldenburg, K.R. (1999) A simple statistical parameter foruse in evaluation and validation of high throughput screening assays. J. Biomol.Screen. 4 : 67–73.
76. Watanabe, K.; Fuse, T.; Asano, I.; Tsukahara, F.; Maru, Y.; Nagata, K.; Kitazato, K.; Kobayashi, N. (2006) Identification of Hsc70 as an influenza virus matrix protein (M1) binding factor involved in the virus life cycle. FEBS Lett. 580: 5785–5790.
77. Hu, Y.; Liu, X.; Zhang, A.; Zhou, H.; Liu, Z.; Chen, H.; Jin, M. (2015) CHD3 facilitates vRNP nuclear export by interacting with NES1 of influenza A virus NS2. Cell. Mol. Life Sci. 72:971–982.
78. Munier, S.; Rolland, T.; Diot, C.; Jacob, Y.; Naffakh, N. (2013) Exploration of binary virus-host interactions using an infectious protein complementation assay. Mol. Cell. Proteom. 12: 2845–2855.
79. Satterly, N.; Tsai, P.L.; van Deursen, J.; Nussenzveig, D.R.; Wang, Y.; Faria, P.A.; Levay, A.; Levy, D.E.; Fontoura, B.M. (2007) Influenza virus targets the mRNA export machinery and the nuclear pore complex. Proc.Natl. Acad. Sci. USA 104:1853–1858.
80. Chutiwitoonchai N, Aida Y. (2016) NXT1, a Novel Influenza A NP Binding Protein, Promotes the Nuclear Export of NP via a CRM1-Dependent Pathway. Viruses.8
81. Uversky VN (2011) Intrinsically disorde red proteins from A to Z. Int J Biochem Cell Biol 43: 1090-1103.
82. Metallo SJ (2010) Intrinsically disordered proteins are potential drug targets. Curr Opin Chem Biol 14: 481-488.
83. Xue B, Mizianty MJ, Kurgan L, Uversky VN (2012) Protein intrinsic disorder as a flexible armor and a weapon of HIV-1. Cell Mol Life Sci 69: 1211-1259.
84. Eisfeld AJ, Neumann G, Kawaoka Y (2015) At the centre: influenza A virus ribonucleoproteins. Nat Rev Microbiol 13: 28-41.
85. Ward JJ, McGuffin LJ, Bryson K, Buxton BF, Jones DT (2004) The DISOPRED server for the prediction of protein disorder. Bioinformatics 20: 2138-2139.
86. Neumann G, Watanabe T, Kawaoka Y (2000) Plasmid-driven formation of influenza virus-like particles. J Virol 74: 547-551.
87. Liang Y, Danzy S, Dao LD, Parslow TG (2012) Mutational analyses of the influenza A virus polymerase subunit PA reveal distinct functions related and unrelated to RNA polymerase activity. PLoS One 7: e29485.
88. Ng AK, Wang JH, Shaw PC (2009) Structure and sequence analysis of influenza A virus nucleoprotein. Sci China C Life Sci 52: 439-449.
89. Chan WH, Ng AK, Robb NC, Lam MK, Chan PK, et al. (2010) Functional analysis of the influenza virus H5N1 nucleoprotein tail loop reveals amino acids that are crucial for oligomerization and ribonucleoprotein activities. J Virol 84: 7337-7345.
90. Nayak DP, Balogun RA, Yamada H, Zhou ZH, Barman S (2009) Influenza virus morphogenesis and budding. Virus Res 143: 147-161.
91. Portela A, Digard P (2002) The influenza virus nucleoprotein: a multifunctional RNA-binding protein pivotal to virus replication. J Gen Virol 83: 723-734
92. Carrasco M, Amorim MJ, Digard P (2004) Lipid raft-dependent targeting of the influenza A virus nucleoprotein to the apical plasma membrane. Traffic 5: 979-992.
93. Hayashi M, Shimada Y, Inomata M, Ohno-Iwashita Y (2006) Detection of cholesterol-rich microdomains in the inner leaflet of the plasma membrane. Biochem Biophys Res Commun 351: 713-718.
94. Takeda M, Leser GP, Russell CJ, Lamb RA (2003) Influenza virus hemagglutinin concentrates in lipid raft microdomains for efficient viral fusion. Proc Natl Acad Sci U S A 100: 14610-14617.
95. DiNitto JP, Cronin TC, Lambright DG (2003) Membrane recognition and targeting by lipid-binding domains. Sci STKE 2003: re16.
96. Varnai P, Balla T (1998) Visualization of phosphoinositides that bind pleckstrin homology domains: calcium- and agonist-induced dynamic changes and relationship to myo-[3H]inositol-labeled phosphoinositide pools. J Cell Biol 143: 501-510.
97. Ono A, Ablan SD, Lockett SJ, Nagashima K, Freed EO (2004) Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane. Proc Natl Acad Sci U S A 101: 14889-14894.
98. Janmey PA, Lindberg U (2004) Cytoskeletal regulation: rich in lipids. Nat Rev Mol Cell Biol 5: 658-666.
99. Simpson-Holley M, Ellis D, Fisher D, Elton D, McCauley J, et al. (2002) A functional link between the actin cytoskeleton and lipid rafts during budding of filamentous influenza virions. Virology 301: 212-225.
100. Schliwa M (1982) Action of cytochalasin D on cytoskeletal networks. J Cell Biol 92: 79-91.
101. Payrastre B, Missy K, Giuriato S, Bodin S, Plantavid M, et al. (2001) Phosphoinositides: key players in cellsignalling, in time and space. cellsignal 13: 377-387.
102. Ferguson CG, James RD, Bigman CS, Shepard DA, Abdiche Y, et al. (2005) Phosphoinositide-containing polymerized liposomes: stable membrane-mimetic vesicles for protein-lipid binding analysis. Bioconjug Chem 16: 1475-1483.
103. Thapa N, Anderson RA (2012) PIP2 signaling, an integrator of cell polarity and vesicle trafficking in directionally migrating cells. Cell Adh Migr 6: 409-412.
104. Wen PJ, Osborne SL, Zanin M, Low PC, Wang HT, et al. (2011) Phosphatidylinositol(4,5)bisphosphate coordinates actin-mediated mobilization and translocation of secretory vesicles to the plasma membrane of chromaffin cells. Nat Commun 2: 491.
105. Rozelle AL, Machesky LM, Yamamoto M, Driessens MH, Insall RH, et al. (2000) Phosphatidylinositol 4,5-bisphosphate induces actin-based movement of raft-enriched vesicles through WASP-Arp2/3. Curr Biol 10: 311-320.
106. Benesch S, Lommel S, Steffen A, Stradal TE, Scaplehorn N, et al. (2002) Phosphatidylinositol 4,5-biphosphate (PIP2)-induced vesicle movement depends on N-WASP and involves Nck, WIP, and Grb2. J Biol Chem 277: 37771-37776.
107. Honda A, Nogami M, Yokozeki T, Yamazaki M, Nakamura H, et al. (1999) Phosphatidylinositol 4-phosphate 5-kinase alpha is a downstream effector of the small G protein ARF6 in membrane ruffle formation. Cell 99: 521-532.
108. Donaldson JG (2003) Multiple roles for Arf6: sorting, structuring, and signaling at the plasma membrane. J Biol Chem 278: 41573-41576.
109. Aikawa Y, Martin TF (2003) ARF6 regulates a plasma membrane pool of phosphatidylinositol(4,5)bisphosphate required for regulated exocytosis. J Cell Biol 162: 647-659.
110. Brown FD, Rozelle AL, Yin HL, Balla T, Donaldson JG (2001) Phosphatidylinositol 4,5-bisphosphate and Arf6-regulated membrane traffic. J Cell Biol 154: 1007-1017.
111. Hurley JH, Boura E, Carlson LA, Rozycki B (2010) Membrane budding. Cell 143: 875-887.
112. Chukkapalli V, Ono A (2011) Molecular determinants that regulate plasma membrane association of HIV-1 Gag. J Mol Biol 410: 512-524.
113. Ali A, Avalos RT, Ponimaskin E, Nayak DP (2000) Influenza virus assembly: effect of influenza virus glycoproteins on the membrane association of M1 protein. J Virol 74: 8709-8719.